Y-mAbs’ Lu-177-based disialoganglioside GD2-targeting program is in phase 1 for small cell lung cancer, melanoma and sarcomas to determine treatment dose, sequence and spacing.

Elixirgen Therapeutics’ Aki Ko joins Erin Harris to detail the company’s Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections.

COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by harnessing the body’s peripheral immune system.

Tessera Therapeutics, a well-funded startup based outside of Boston, announced Friday that it developed a lipid nanoparticle that shuttles a gene editing therapy directly to the bone marrow of mice.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.

Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with obesity, and another Phase II in people with pre-diabetes.

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim’s not in software development anymore.